Intech Investment Management LLC Acquires New Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Intech Investment Management LLC bought a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the third quarter, HoldingsChannel reports. The fund bought 42,094 shares of the company’s stock, valued at approximately $85,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TSHA. GSA Capital Partners LLP increased its stake in shares of Taysha Gene Therapies by 64.7% in the third quarter. GSA Capital Partners LLP now owns 233,560 shares of the company’s stock worth $469,000 after acquiring an additional 91,755 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Taysha Gene Therapies in the third quarter valued at about $416,000. Privium Fund Management B.V. increased its position in Taysha Gene Therapies by 21.8% in the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock worth $241,000 after purchasing an additional 21,500 shares during the last quarter. Quantum Private Wealth LLC raised its stake in shares of Taysha Gene Therapies by 5.1% during the 3rd quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock worth $1,543,000 after purchasing an additional 37,096 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after purchasing an additional 17,446 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $2.48 on Monday. Taysha Gene Therapies, Inc. has a 1 year low of $1.19 and a 1 year high of $4.32. The company has a fifty day simple moving average of $2.11 and a 200 day simple moving average of $2.38. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The company has a market cap of $508.25 million, a P/E ratio of 35.43 and a beta of 0.79.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital restated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Canaccord Genuity Group lifted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies has a consensus rating of “Buy” and a consensus target price of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.